Bevacizumab, marketed under the trade name Avastin, is a type of targeted therapy known as a monoclonal antibody. It specifically inhibits vascular endothelial growth factor (VEGF), a protein that promotes the growth of new blood vessels (angiogenesis). By blocking VEGF, bevacizumab aims to reduce the blood supply to tumors, thereby inhibiting their growth.
